Oral JAK inhibitor baricitinib effective in JIA

被引：0
|
作者：
Jessica McHugh
机构：
[1] Nature Reviews Rheumatology,
来源：
Nature Reviews Rheumatology | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
引用
收藏
页码：539 / 539
相关论文
共 50 条
  • [11] JAK inhibitor effective in rheumatoid arthritis
    Yvonne Bordon
    Nature Reviews Immunology, 2012, 12 (9) : 621 - 621
  • [12] Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
    Mogul, Amanda
    Corsi, Katherine
    McAuliffe, Laura
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 947 - 953
  • [13] Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
    Brendan L. Thoms
    Jeanne Gosselin
    Bonita Libman
    Benjamin Littenberg
    Ralph C. Budd
    SN Comprehensive Clinical Medicine, 4 (1)
  • [14] Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
    Arnold, Rouven
    Vehns, Elena
    Randl, Hannah
    Djabali, Karima
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)
  • [15] A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
    Papp, K. A.
    Menter, M. A.
    Raman, M.
    Disch, D.
    Schlichting, D. E.
    Gaich, C.
    Macias, W.
    Zhang, X.
    Janes, J. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (06) : 1266 - 1276
  • [16] Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching
    Dhir, Bhawuk
    Meena, Sumitra Kumari
    Sardana, Kabir
    Sharath, Savitha
    PEDIATRIC DERMATOLOGY, 2024, 41 (01) : 139 - 140
  • [17] Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
    Jabbari, Ali
    Dai, Zhenpeng
    Xing, Luzhou
    Cerise, Jane E.
    Ramot, Yuval
    Berkun, Yackov
    Sanchez, Gina A. Montealegre
    Goldbach-Mansky, Raphaela
    Christiano, Angela M.
    Clynes, Raphael
    Zlotogorski, Abraham
    EBIOMEDICINE, 2015, 2 (04): : 351 - 355
  • [18] Which is the ideal JAK inhibitor for alopecia areata - Baricitinib, tofacitinib, ritlecitinib or ifidancitinib-Revisiting the immunomechanisms of the JAK pathway
    Sardana, Kabir
    Bathula, Savitha
    Khurana, Ananta
    INDIAN DERMATOLOGY ONLINE JOURNAL, 2023, 14 (04) : 465 - 474
  • [19] BARICITINIB Tyrosine-Protein Kinase JAK1/JAK2 Inhibitor Treatment of Rheumatoid Arthritis
    Gras, Jordi
    DRUGS OF THE FUTURE, 2013, 38 (09) : 611 - 617
  • [20] BARICITINIB: JAK INHIBITION FOR RHEUMATOID ARTHRITIS
    Gras, J.
    DRUGS OF TODAY, 2016, 52 (10) : 543 - 550
12345